Logo image of XLRN

Acceleron Pharma (XLRN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XLRN -

178.75
-0.93 (-0.52%)
Last: 11/19/2021, 8:33:57 PM
179.92
+1.17 (+0.65%)
After Hours: 11/19/2021, 8:33:57 PM
Fundamental Rating

3

Overall XLRN gets a fundamental rating of 3 out of 10. We evaluated XLRN against 530 industry peers in the Biotechnology industry. The financial health of XLRN is average, but there are quite some concerns on its profitability. XLRN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XLRN has reported negative net income.
XLRN Yearly Net Income VS EBIT VS OCF VS FCFXLRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -32.35%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLRN Yearly ROA, ROE, ROICXLRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 -10 -20 -30 -40

1.3 Margins

XLRN does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -226%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLRN Yearly Profit, Operating, Gross MarginsXLRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, XLRN has more shares outstanding
XLRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XLRN Yearly Shares OutstandingXLRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 20M 40M 60M
XLRN Yearly Total Debt VS Total AssetsXLRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 91.90 indicates that XLRN is not in any danger for bankruptcy at the moment.
XLRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 91.9
ROIC/WACCN/A
WACCN/A
XLRN Yearly LT Debt VS Equity VS FCFXLRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 12.14 indicates that XLRN has no problem at all paying its short term obligations.
A Quick Ratio of 12.14 indicates that XLRN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 12.14
Quick Ratio 12.14
XLRN Yearly Current Assets VS Current LiabilitesXLRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

XLRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.15%.
Looking at the last year, XLRN shows a small growth in Revenue. The Revenue has grown by 6.40% in the last year.
XLRN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.58% yearly.
EPS 1Y (TTM)-76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.76%
Revenue 1Y (TTM)6.4%
Revenue growth 3Y90.04%
Revenue growth 5Y38.58%
Sales Q2Q%51.59%

3.2 Future

XLRN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.07% yearly.
XLRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.39% yearly.
EPS Next Y-41.56%
EPS Next 2Y-8.05%
EPS Next 3Y8.29%
EPS Next 5Y-3.07%
Revenue Next Year41.05%
Revenue Next 2Y47.46%
Revenue Next 3Y45.08%
Revenue Next 5Y45.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
XLRN Yearly Revenue VS EstimatesXLRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
XLRN Yearly EPS VS EstimatesXLRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XLRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XLRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLRN Price Earnings VS Forward Price EarningsXLRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -41
XLRN Per share dataXLRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.05%
EPS Next 3Y8.29%

More info and screens

0

5. Dividend

5.1 Amount

XLRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Acceleron Pharma

NASDAQ:XLRN (11/19/2021, 8:33:57 PM)

After market: 179.92 +1.17 (+0.65%)

178.75

-0.93 (-0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)02-28 2022-02-28/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners17.97%
Ins Owner Change0%
Market Cap10.89B
Revenue(TTM)112.77M
Net Income(TTM)-254.86M
Analysts72.94
Price Target182.68 (2.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.59
P/FCF N/A
P/OCF N/A
P/B 15.17
P/tB N/A
EV/EBITDA -41
EPS(TTM)-4.21
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.85
BVpS11.79
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -226%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.14
Quick Ratio 12.14
Altman-Z 91.9
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.76%
EPS Next Y-41.56%
EPS Next 2Y-8.05%
EPS Next 3Y8.29%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)6.4%
Revenue growth 3Y90.04%
Revenue growth 5Y38.58%
Sales Q2Q%51.59%
Revenue Next Year41.05%
Revenue Next 2Y47.46%
Revenue Next 3Y45.08%
Revenue Next 5Y45.39%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Acceleron Pharma / XLRN FAQ

What is the fundamental rating for XLRN stock?

ChartMill assigns a fundamental rating of 3 / 10 to XLRN.


Can you provide the valuation status for Acceleron Pharma?

ChartMill assigns a valuation rating of 0 / 10 to Acceleron Pharma (XLRN). This can be considered as Overvalued.


What is the profitability of XLRN stock?

Acceleron Pharma (XLRN) has a profitability rating of 1 / 10.


What is the financial health of Acceleron Pharma (XLRN) stock?

The financial health rating of Acceleron Pharma (XLRN) is 6 / 10.